Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy.

Categoría Estudio primario
RevistaCureus
Año 2021
Immune checkpoint blockade is a rapidly expanding therapeutic modality in oncology. However, its adverse effects extend beyond the cytotoxicity of conventional chemotherapy. Pneumotoxicity associated with immune checkpoint therapy presents a diagnostic conundrum that has been further complicated by the COVID-19 pandemic. We report a case of a patient with metastatic urothelial carcinoma who developed diffuse alveolar hemorrhage (DAH) following treatment with avelumab.
Epistemonikos ID: 82a69c89b0b4d7fa42c8f0020275ce57477d799c
First added on: Jul 27, 2021